^{NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR ANY JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.}
 

SHOP APOTHEKE EUROPE continues its fast growth: Q4 sales up 38%, full year 2020 growth 38.1%.

• Preliminary sales growth of 38.0% to EUR 264.8 million in Q4 and of 38.1% to EUR 968.2 million for the full year.
• Sales for the DACH Segment +33.7% and for the International Segment +68.2% in Q4; +32.5% and 78.3%, respectively, for the full year.
• Number of active customers increased to 6.3 million. Up 0.4 million in Q4 and up 1.6 million during 2020.
• Growth pace continues with a good start into 2021

Venlo, 11 January 2021. SHOP APOTHEKE EUROPE N.V. exceeded its ambitious growth targets for the 2020 financial year (balance sheet date: Dec. 31), according to preliminary unaudited calculations: With an increase in group sales of 38.1% to EUR 968.2 million for 2020, growth was at the high end of the latest guidance of at least 35%, which had been raised three times throughout the year. For Q4, sales were EUR 264.8 million, 38.0% growth compared to the corresponding period 2019. SHOP APOTHEKE EUROPE gained 0.4 million active customers in Q4 and 1.6 million during the full year, reaching 6.3 million active customers at the end of 2020.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE: "2020 was a challenging year for us, but also an outstanding one. Thanks to the smart thinking and dedicated work of our employees, we were able to manage the huge increase in order volumes while at the same time continuing to push ahead with a broad range of strategic projects. All in all, we have made significant progress in transforming SHOP APOTHEKE EUROPE from an online pharmacy retailer into a customer-centric e-pharmacy platform, which we have further advanced with the recent acquisition of SMARTPATIENT."

In the DACH Segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE recorded 33.7% growth in Q4, resulting in sales of EUR 263.9 million. In the full year 2020, sales grew by 32.5% to EUR 815.5 million. In the International Segment (France, Belgium, Italy and the Netherlands), SHOP APOTHEKE EUROPE increased its sales by 68.2% to EUR 41.0 million in Q4 and by 78.3% to EUR 152.6 million in the full year.

The sale of prescription drugs (Rx) increased by 17.6 % year-on-year, from EUR 186.5 million in 2019 to EUR 219.3 million in 2020.

CFO Jasper Eenhorst comments: "We were able to raise our sales growth guidance three times last year because we seized the opportunities we saw and were quick to make the right decisions. This took us close to the billion-euro mark in sales in 2020. With the ongoing move to our new logistics centre and our fast-growing base of active, happy, customers we are also well positioned for continued growth in 2021."

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the complete annual report for the 2020 financial year on 3 March 2021.
 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of the leading and fastest-growing online pharmacies in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the areas of OTC, beauty and personal care products as well as prescription drugs is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE operates online pharmacies in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland at this moment. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 6.3 million active customers (31 December 2020) fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and has moved up to the MDAX index on 21 September 2020.

PRESS CONTACTS.
Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: presse@shop-apotheke.com

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: presse@shop-apotheke.com


DISCLAIMER.

This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of SHOP APOTHEKE EUROPE N.V. is not taking place.

Statements contained herein could constitute so-called 'forward-looking statements'. Forward-looking statements can be recognized by words such as 'might,' 'will,' 'should,' 'plans,' 'anticipates,' 'anticipates,' 'estimates,' 'believes,' 'intends,' 'aims,' 'aim' or their negative form or corresponding modifications and comparable terms.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.